Clinical trial: Comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 7, 2007, Pages 1077-1082

  Sebastiani, G ^a,b   Ferrari, A ^b   Boccato, S ^b   Pistis, R ^b   Alberti, A ^a,b  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS; INTERFERON ALFA-2B; MALE; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 34548693657     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03451.x     Document Type: Article

References (12)

1. Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol 2003 38 (Suppl. 1 S104 18.
2. NIH Consensus Development Panel. Management of hepatitis C: 2002; June 10-12, 2002. NIH consensus statement. Available at: http://consensus.nih.gov/ cons/116/116cdcintro.htm. Accessed March 3, 2004.
3. Luxon BA, Grace M, Brassard D, et al. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002 24 : 1363 83.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 65.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
6. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000 32 : 647 53.
7. Ferenci P. Weight-based dosing of pegylated interferon-alfa in chronic hepatitis C Just a marketing "gag"? Dig Liver Dis 2003 35 : 601 6.
8. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotypes 1. J Viral Hepat 2003 10 : 271 6.
9. Buti M, Esteban R. Does twice-weekly administration of peginterferon alfa-2b really improve viral kinetics in patients with chronic hepatitis C genotype 1? J Viral Hepat 2004 11 : 187 90.
10. Jacobson IM, McHutchison J. Response to Article by Formann et al. (2003). J Viral Hepat 2004 11 : 187 90.
11. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
12. Lurie Y, Rouzier-Panis R, Webster GJM, et al. Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2005 3 : 610 5.